Aligos Therapeutics Reports Q2 EPS of $1.53, Misses Consensus
ByAinvest
Friday, Aug 8, 2025 7:39 am ET1min read
ALGS--
The company's Phase 2 B-SUPREME study for ALG-000184 is progressing, with regulatory approvals across several countries and dosing expected to commence soon. Phase 1 data presented at the EASL meeting suggested that ALG-000184 has the potential to replace standard of care treatment for chronic HBV infection and may become the backbone of treatments aimed at a functional cure [2].
Over the last four quarters, Aligos Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once. The company's shares have lost about 80.2% since the beginning of the year versus the S&P 500's gain of 7.1% [1].
The sustainability of the stock's immediate price movement will depend on management's commentary on the earnings call. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock. The Medical - Biomedical and Genetics industry is currently in the bottom 42% of the 250 plus Zacks industries [1].
References:
[1] https://www.nasdaq.com/articles/aligos-therapeutics-inc-algs-reports-q2-loss-misses-revenue-estimates
[2] https://www.biospace.com/press-releases/alkeus-pharmaceuticals-announces-presentation-of-positive-interim-tease-3-study-data-in-early-stage-stargardt-disease-patients-treated-with-oral-gildeuretinol
Aligos Therapeutics reported Q2 EPS of ($1.53) and revenue of $965,000, exceeding consensus estimates of ($2.54) and $433,330. The company's Phase 2 B-SUPREME study for ALG-000184 is underway, with regulatory approvals across several countries and dosing expected to commence soon. The Phase 1 data presented at the EASL meeting suggests that ALG-000184 has the potential to replace standard of care treatment for chronic HBV infection and may become the backbone of treatments aimed at a functional cure.
Aligos Therapeutics, Inc. (ALGS) reported a Q2 2025 loss of $1.53 per share, surpassing the Zacks Consensus Estimate of a loss of $2.35 [1]. This compares to earnings of $0.75 per share a year ago. The company also reported revenues of $0.97 million for the quarter, missing the Zacks Consensus Estimate by 3.5% [1]. These figures are adjusted for non-recurring items.The company's Phase 2 B-SUPREME study for ALG-000184 is progressing, with regulatory approvals across several countries and dosing expected to commence soon. Phase 1 data presented at the EASL meeting suggested that ALG-000184 has the potential to replace standard of care treatment for chronic HBV infection and may become the backbone of treatments aimed at a functional cure [2].
Over the last four quarters, Aligos Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once. The company's shares have lost about 80.2% since the beginning of the year versus the S&P 500's gain of 7.1% [1].
The sustainability of the stock's immediate price movement will depend on management's commentary on the earnings call. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock. The Medical - Biomedical and Genetics industry is currently in the bottom 42% of the 250 plus Zacks industries [1].
References:
[1] https://www.nasdaq.com/articles/aligos-therapeutics-inc-algs-reports-q2-loss-misses-revenue-estimates
[2] https://www.biospace.com/press-releases/alkeus-pharmaceuticals-announces-presentation-of-positive-interim-tease-3-study-data-in-early-stage-stargardt-disease-patients-treated-with-oral-gildeuretinol
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet